Skip to main content

Table 1 Non-compartmental analysis parameter estimates of the exposure of ferroquine and SSR97213

From: A Phase II pilot trial to evaluate safety and efficacy of ferroquine against early Plasmodium falciparum in an induced blood-stage malaria infection study

 

Ferroquine

SSR97213

Cmax (ng/mL)

 Geometric mean

155

89

 Log-linear CIs

(94–257)

(49–162)

Tmax (h)

 Median (range)

6 (4–8)

8 (4–12) one subject at 48 h)

C144 h (ng/mL)

 Geometric mean

26

26

 Log-linear CIs

(21–32)

(19–36)

Half-life (h)

 Geometric mean

262 (10.9 days)

661 (27.5 days)

 Range

(204–315)

(295–1349)

AUC144 h (ng/mL)

 Geometric mean

6893

5525

 Log-linear CIs

(5378–8834)

(3883–7861)

AUC0−last (ng/mL)

 Geometric mean

12,406

12,247

 Range

(9259–17,826)

(6449–19,975)

AUC0−Inf (ng/mL)

 Geometric mean

16,631

31,006

 Range

(11,314–25,091)

(10,061–55,768)